Ensysce Biosciences Inc
NASDAQ:ENSC

Watchlist Manager
Ensysce Biosciences Inc Logo
Ensysce Biosciences Inc
NASDAQ:ENSC
Watchlist
Price: 0.862 USD -3.04% Market Closed
Market Cap: $3.1m

Operating Margin

-245.9%
Current
Improving
by 189.6%
vs 3-y average of -435.5%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-245.9%
=
Operating Income
$-11m
/
Revenue
$4.5m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-245.9%
=
Operating Income
$-11m
/
Revenue
$4.5m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Ensysce Biosciences Inc
NASDAQ:ENSC
3.2m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 89% of companies in the United States of America
Percentile
11th
Based on 14 112 companies
11th percentile
-245.9%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Ensysce Biosciences Inc
Glance View

Market Cap
3.1m USD
Industry
Biotechnology

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in La Jolla, California. The company went IPO on 2017-12-01. The firm is engaged in the development of small and large molecule drug delivery platforms targeting pain and cancer markets. Ensysce’s products include PF614 and PF614- Multi-Pill Abuse Resistant (MPAR). PF614 is a Trypsin-Activated Abuse Protection (TAAP) oxycodone prodrug that is a biologically inactive compound which can be metabolized in the body to produce a drug with demonstrable features aimed at resisting both oral and non-oral modes of prescription drug abuse. TAAP technology seeks to remove the ability of a user to abuse PF614 intravenously or intra-nasally. PF614-MPAR is a combination product of PF614 and nafamostat has designed to limit abuse potential by providing resistance to use through injection or inhalation and to provide overdose protection against excessive oral ingestion. Ensysce initiated a Phase I clinical trial for PF614-MPAR to evaluate safety and Pharmacokinetics in healthy.

ENSC Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-245.9%
=
Operating Income
$-11m
/
Revenue
$4.5m
What is Ensysce Biosciences Inc's current Operating Margin?

The current Operating Margin for Ensysce Biosciences Inc is -245.9%, which is above its 3-year median of -435.5%.

How has Operating Margin changed over time?

Over the last 3 years, Ensysce Biosciences Inc’s Operating Margin has increased from -734.4% to -245.9%. During this period, it reached a low of -961.5% on Dec 31, 2022 and a high of -89.7% on Jun 30, 2025.

Back to Top